Bosulif Recommended by SMC for Chronic Myeloid Leukaemia
The Scottish Medicines Consortium (SMC) has approved Pfizer’s Bosulif (bosutinib) for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukaemia, within NHS Scotland. The treatment has been approved for patients who have previously been treated with one or more tyrosine kinase inhibitors, and for whom